Global Trial in APG2575 for Patients With CLL/SLL

Inclusion Criteria

• •1. \- Age ≥ 18 years.
• •2. . Patients that have documented CLL/SLL who meet iwCLL 2018 criteria for CLL treatment guidelines are eligible for treatment and must be receiving BTKi monotherapy for at least 12 months
• •3. ECOG Performance Status grade 0-2
• •4. Adequate bone marrow function independent of growth factor or transfusion support within 2 weeks of screening initiation as follows:
• •* Absolute neutrophil count ≥ 1.0 × 109/L
• •* Platelet counts ≥ 75 × 109/L; in cases of thrombocytopenia
• •* Total hemoglobin ≥ 9 g/dL,
• •5. Adequate renal function
• •* Creatinine clearance must be \> 50 ml/min directly measured with 24hr urine collection or calculated according to the modified formula of Cockcroft and Gault (for men: GFR ≈ ((140 - age) x actual body weight)/(72 x creatinine), for women x 0.85) or an equally accurate method.
• •6. Adequate liver function as indicated by:
• •* Total bilirubin ≤ 1.5 x ULN, except patients with known Gilbert's Syndrome
• •* Aspartate aminotransferase (AST) ≤ 2.5 x the institutional ULN value
• •* Alanine aminotransferase (ALT) ≤ 2.5 x the institutional ULN value,
• •* International normalized Ratio (INR), Prothrombin Time (PT) or Activated Partial Thromboplastin time (APTT) ≤ 1.5×ULN.
• •7. Ability and willingness to provide written informed consent and to adhere to the study visit schedule and other protocol requirements